These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 23200825)
1. The transcription factor Jdp2 controls bone homeostasis and antibacterial immunity by regulating osteoclast and neutrophil differentiation. Maruyama K; Fukasaka M; Vandenbon A; Saitoh T; Kawasaki T; Kondo T; Yokoyama KK; Kidoya H; Takakura N; Standley D; Takeuchi O; Akira S Immunity; 2012 Dec; 37(6):1024-36. PubMed ID: 23200825 [TBL] [Abstract][Full Text] [Related]
2. JDP2 suppresses adipocyte differentiation by regulating histone acetylation. Nakade K; Pan J; Yoshiki A; Ugai H; Kimura M; Liu B; Li H; Obata Y; Iwama M; Itohara S; Murata T; Yokoyama KK Cell Death Differ; 2007 Aug; 14(8):1398-405. PubMed ID: 17464331 [TBL] [Abstract][Full Text] [Related]
3. Jun dimerization protein 2 (JDP2), a member of the AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKL. Kawaida R; Ohtsuka T; Okutsu J; Takahashi T; Kadono Y; Oda H; Hikita A; Nakamura K; Tanaka S; Furukawa H J Exp Med; 2003 Apr; 197(8):1029-35. PubMed ID: 12707301 [TBL] [Abstract][Full Text] [Related]
4. The transcription factor T-box 3 regulates colony-stimulating factor 1-dependent Jun dimerization protein 2 expression and plays an important role in osteoclastogenesis. Yao C; Yao GQ; Sun BH; Zhang C; Tommasini SM; Insogna K J Biol Chem; 2014 Mar; 289(10):6775-6790. PubMed ID: 24394418 [TBL] [Abstract][Full Text] [Related]
5. Regulation of histone acetylation and nucleosome assembly by transcription factor JDP2. Jin C; Kato K; Chimura T; Yamasaki T; Nakade K; Murata T; Li H; Pan J; Zhao M; Sun K; Chiu R; Ito T; Nagata K; Horikoshi M; Yokoyama KK Nat Struct Mol Biol; 2006 Apr; 13(4):331-8. PubMed ID: 16518400 [TBL] [Abstract][Full Text] [Related]
6. The ubiquitously expressed bZIP inhibitor, JDP2, suppresses the transcription of its homologue immediate early gene counterpart, ATF3. Weidenfeld-Baranboim K; Hasin T; Darlyuk I; Heinrich R; Elhanani O; Pan J; Yokoyama KK; Aronheim A Nucleic Acids Res; 2009 Apr; 37(7):2194-203. PubMed ID: 19233874 [TBL] [Abstract][Full Text] [Related]
7. The pivotal role of the alternative NF-kappaB pathway in maintenance of basal bone homeostasis and osteoclastogenesis. Soysa NS; Alles N; Weih D; Lovas A; Mian AH; Shimokawa H; Yasuda H; Weih F; Jimi E; Ohya K; Aoki K J Bone Miner Res; 2010 Apr; 25(4):809-18. PubMed ID: 19839765 [TBL] [Abstract][Full Text] [Related]
8. Histone chaperone Jun dimerization protein 2 (JDP2): role in cellular senescence and aging. Huang YC; Saito S; Yokoyama KK Kaohsiung J Med Sci; 2010 Oct; 26(10):515-31. PubMed ID: 20950777 [TBL] [Abstract][Full Text] [Related]
9. The AP-1 repressor protein, JDP2, potentiates hepatocellular carcinoma in mice. Bitton-Worms K; Pikarsky E; Aronheim A Mol Cancer; 2010 Mar; 9():54. PubMed ID: 20214788 [TBL] [Abstract][Full Text] [Related]
10. MS-275, a benzamide histone deacetylase inhibitor, prevents osteoclastogenesis by down-regulating c-Fos expression and suppresses bone loss in mice. Kim HN; Lee JH; Jin WJ; Ko S; Jung K; Ha H; Lee ZH Eur J Pharmacol; 2012 Sep; 691(1-3):69-76. PubMed ID: 22846626 [TBL] [Abstract][Full Text] [Related]
11. ATF3 and JDP2 deficiency in cancer associated fibroblasts promotes tumor growth via SDF-1 transcription. Avraham S; Korin B; Aviram S; Shechter D; Shaked Y; Aronheim A Oncogene; 2019 May; 38(20):3812-3823. PubMed ID: 30670778 [TBL] [Abstract][Full Text] [Related]
12. Histone modification activities of JDP2 associated with retinoic acid-induced differentiation of F9 cells. Pan J; Jin C; Murata T; Yokoyama KK Nucleic Acids Symp Ser (Oxf); 2004; (48):189-90. PubMed ID: 17150542 [TBL] [Abstract][Full Text] [Related]
13. FIAT represses ATF4-mediated transcription to regulate bone mass in transgenic mice. Yu VW; Ambartsoumian G; Verlinden L; Moir JM; Prud'homme J; Gauthier C; Roughley PJ; St-Arnaud R J Cell Biol; 2005 May; 169(4):591-601. PubMed ID: 15911876 [TBL] [Abstract][Full Text] [Related]
14. The deficiency of immunoregulatory receptor PD-1 causes mild osteopetrosis. Nagahama K; Aoki K; Nonaka K; Saito H; Takahashi M; Varghese BJ; Shimokawa H; Azuma M; Ohya K; Ohyama K Bone; 2004 Nov; 35(5):1059-68. PubMed ID: 15542030 [TBL] [Abstract][Full Text] [Related]
15. The transcription factor FBI-1/OCZF/LRF is expressed in osteoclasts and regulates RANKL-induced osteoclast formation in vitro and in vivo. Kukita A; Kukita T; Nagata K; Teramachi J; Li YJ; Yoshida H; Miyamoto H; Gay S; Pessler F; Shobuike T Arthritis Rheum; 2011 Sep; 63(9):2744-54. PubMed ID: 21590684 [TBL] [Abstract][Full Text] [Related]
16. Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation. Zaiss MM; Sarter K; Hess A; Engelke K; Böhm C; Nimmerjahn F; Voll R; Schett G; David JP Arthritis Rheum; 2010 Aug; 62(8):2328-38. PubMed ID: 20506516 [TBL] [Abstract][Full Text] [Related]
17. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014 [TBL] [Abstract][Full Text] [Related]
18. The bZIP repressor proteins, c-Jun dimerization protein 2 and activating transcription factor 3, recruit multiple HDAC members to the ATF3 promoter. Darlyuk-Saadon I; Weidenfeld-Baranboim K; Yokoyama KK; Hai T; Aronheim A Biochim Biophys Acta; 2012; 1819(11-12):1142-53. PubMed ID: 22989952 [TBL] [Abstract][Full Text] [Related]